CSF2 and neoplasm: By adapting RNAi methodology in vivo, we demonstrated that a specific loss of GMCSFRα in DRG led to a reduction in bone tumor–evoked pain without interfering with the tumor growth, indicating that GMCSF signaling in peripheral nerves contributes substantially to cancer pain[8].